SCHEMBL2992898

SCHEMBL2992898

Cc1ncc(Oc2ccc(C(N)=O)cc2F)c2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.43
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
MAPK14 Q16539 1/20 0.41
OPRM1 P35372 6/20 0.40
OPRK1 P41145 6/20 0.40
OPRD1 P41143 5/20 0.40
KCNQ3 O43525 1/20 0.39
KCNQ2 O43526 1/20 0.39
KCNE1 P15382 1/20 0.39
KCNQ1 P51787 1/20 0.39
BRD4 O60885 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38
KCNH2 Q12809 1/20 0.38
FEN1 P39748 1/20 0.38
AR P10275 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2994036 0.83 PARP10 (0.41) PARP10LMNAMAPTMAPK14OPRM1
SCHEMBL2994013 0.79 NNMT (0.52) OPRM1OPRK1OPRD1KCNH2
SCHEMBL2988681 0.76 PARP10 (0.37) PARP10LMNAMAPTOPRM1OPRK1
SCHEMBL2998027 0.75 LMNA (0.46) PARP10LMNAMAPTMAPK14OPRM1
SCHEMBL2984258 0.75 AR (0.42) FEN1ARALDH1A1ESR1
SCHEMBL2988683 0.74 OPRK1 (0.44) OPRM1OPRK1OPRD1KCNH2
SCHEMBL30289581 0.73 PARP10 (0.67) PARP10LMNAOPRM1OPRK1OPRD1
SCHEMBL2995697 0.72 PARP10 (0.44) PARP10LMNAMAPTOPRM1OPRK1
SCHEMBL29640717 0.71 HTT (0.53) PARP10LMNAOPRM1OPRK1KCNQ3
SCHEMBL21628730 0.71 PARP10 (0.59) PARP10LMNAOPRM1OPRK1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278442-B2 Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders PROSIDION LIMITED (GB) 2012-10-02 US disclosed
US-8278442-B2 Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders PROSIDION LIMITED (GB) 2012-10-02 US disclosed
US-20100173886-A1 BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2010-07-08 US disclosed
US-20100173886-A1 BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2010-07-08 US disclosed
US-20100173886-A1 BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2010-07-08 US disclosed
EP-2152671-A1 BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Prosidion Limited (GB) 2010-02-17 EP disclosed
WO-2008142454-A1 BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2008-11-27 WO disclosed
WO-2008142454-A1 BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173886-A1 BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS OPRM1, OPRK1, OPRD1 PARP10 3869/4885LMNA 4221/4885MAPT 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.